News for Nuo Therapeutics, Inc. (AURX)

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. ( AURX) (”œNuo”), a commercial stage medical device company pioneering leading-edge biod

Nuo Therapeutics (OTCQB: AURX) has signed an exclusive distribution agreement with Smith+Nephew for the U.S. wound care market. The five-year deal inclu

Nuo Therapeutics, Inc. (AURX) has announced a landmark agreement under which its Aurix System will become the exclusive platelet-rich plasma therapy for PAM Hea

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an i

Charles E. Sheedy buys $93,750 of Nuo Therapeutics stock

Nuo Therapeutics executive buys $75,000 in company stock

“Molecular Biology Enzymes, Kits & Reagents Market” from 2024-2034 with covered segments (Molecular Biology Enzymes, Kits & Reagents Market, By Product...

“Platelet Rich Plasma Market” from 2024-2034 with covered segments (Platelet Rich Plasma Market, By Type (Pure Platelet-rich Plasma, Leukocyte-rich...

/PRNewswire/ -- The "Global Autologous Wound Patches Market by Type (Platelet Rich Fibrin, Platelet Rich Plasma), Wound (Acute Wounds, Chronic Wounds), End-Use...

Platelet-rich plasma (PRP) demand is being driven primarily by an increase in the number of patients suffering from orthopedic diseases, sports injuries, acute...

HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering...

Broad equity incentive agreement established with Pacific Medical, Inc. including initial equity purchase Favorable initial progress on establishing...

HOUSTON, Feb. 04, 2022 -- Nuo Therapeutics, Inc. announced that it is aware of an unsolicited “mini-tender” offer by Alternative Liquidity Index, LP to purchase up to 1,820,000... | February 4, 2022